Batch record requirements for FDA-regulated manufacturers are set out primarily in 21 CFR Part 211 for finished pharmaceuticals, Part 820 for medical devices, and Part 111 for dietary supplements. Each product type has its own rule, but the core obligation is the same: create a master production record that acts as the blueprint, generate an individual batch production record for every run that captures what actually happened, and hold the batch until the quality unit reviews and releases it. Every entry must be attributable, contemporaneous, and preserved for at least a year past the batch’s expiration date.
Which Regulation Applies to Your Product
Finished drug manufacturers fall under 21 CFR Part 211, the current Good Manufacturing Practice rules that cover component handling through packaging and labeling.1eCFR. 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals Device makers work under 21 CFR Part 820, which the Quality Management System Regulation overhauled effective February 2, 2026, incorporating ISO 13485:2016 by reference.2Food and Drug Administration. Quality Management System Regulation (QMSR) Non-compliance renders a device adulterated under the Federal Food, Drug, and Cosmetic Act, exposing both the product and responsible individuals to enforcement.3eCFR. 21 CFR Part 820 – Quality Management System Regulation
Dietary supplement manufacturers follow 21 CFR Part 111, which requires a written master manufacturing record for each unique formulation and batch size, plus a batch production record for every run.4eCFR. 21 CFR Part 111 Subpart I – Production and Process Control System: Requirements for the Batch Production Record Part 111 goes further than Part 211 on personnel accountability, requiring the initials of one person to weigh a component, a second to verify the weight, a third to add it to the batch, and a fourth to verify the addition.
What the Master Production Record Must Contain
Before manufacturing begins, the company must draft a master production and control record. Under 21 CFR 211.186, that record must include:
- Product name, strength, and dosage form description
- Weight or measure of each active ingredient per dosage unit, plus a full component list with names or codes specific enough to flag special quality characteristics
- Weight or measure of every component using a single measurement system, with any calculated excesses noted
- Theoretical yield at appropriate processing phases, including the maximum and minimum percentages that trigger a mandatory investigation if exceeded
- Complete processing steps, sampling and testing procedures, specifications, and special precautions
- Descriptions of containers and closures, plus specimens or copies of all labeling, signed and dated by the person who approved them
The yield thresholds do real work. Set the acceptable range too wide and contamination or dispensing errors slip through; set it too narrow and every run triggers an investigation under 21 CFR 211.192.5eCFR. 21 CFR 211.186 – Master Production and Control Records
What Each Batch Record Must Document
The individual batch production and control record captures what happened during a specific run. Under 21 CFR 211.188, the record must document that each significant manufacturing, processing, packing, or holding step was completed, and must include:
- A unique batch or lot number linking the finished product to its raw materials
- The date each significant step was performed
- Identification of each major piece of equipment and production line used
- Specific identification of each batch of component or in-process material, with weights and measures used
- Actual yield and the percentage of theoretical yield
- Identification of the persons performing, directly supervising, or checking each significant step
- In-process and laboratory control results
- Complete labeling records, including specimens of all labeling used
- Inspection of the packaging and labeling area before and after use
A point that trips people up: the regulation requires the date of each significant step, not the clock time.6eCFR. 21 CFR 211.188 – Batch Production and Control Records Many manufacturers record timestamps as a best practice, and some internal SOPs demand it, but the federal text specifies dates.
Second-Person Verification and Automated Equipment
Critical steps require a second person to independently verify and sign off. The batch record identifies both the operator and the checker. This dual-verification approach catches errors that a single operator might miss, particularly during weighing and dispensing, where a misread decimal ruins a batch.
Automated equipment can satisfy the two-person requirement under 21 CFR 211.68 if the system is routinely calibrated, inspected, and checked under a written program. When automation replaces a human check, the equipment must be validated, calibration checks must be documented, and controls must prevent unauthorized changes to master records stored in computers. Backup files of all entered data must also be maintained.7eCFR. 21 CFR 211.68 – Automatic, Mechanical, and Electronic Equipment
Quality Control Review Before Release
No batch reaches the market before the quality control unit reviews the entire production and control record, including packaging and labeling documentation, under 21 CFR 211.192.8eCFR. 21 CFR 211.192 – Production Record Review Reviewers check every entry, signature, and data point against the master record.
Any unexplained discrepancy triggers a thorough investigation. So does an actual yield percentage that falls outside the range set in the master record. The same obligation applies to any batch or component that fails to meet specifications, even after the batch has shipped. The investigation must extend beyond the single troubled batch to other batches of the same product and other products that may be connected to the failure. A written record of the investigation, including conclusions and follow-up, must be kept. Until every discrepancy is resolved, the batch stays quarantined.
Investigating Out-of-Specification Results
When laboratory testing returns a result outside established specifications, the manufacturer takes on obligations that go beyond the general investigation requirement. The FDA defines an out-of-specification (OOS) result broadly: any test result outside the specifications or acceptance criteria in drug applications, drug master files, official compendia, or manufacturer-set standards. In-process results outside established specifications also qualify.9Food and Drug Administration. Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production
The lab first assesses whether the result could stem from a testing error such as instrument malfunction, sample preparation mistake, or calculation error. If no lab error explains the result, the investigation expands to the manufacturing process, reviewing the batch record for deviations, equipment logs for anomalies, and environmental monitoring data. Every step must be documented in writing with clear conclusions about root cause and corrective action. Incomplete OOS investigations are among the most frequent observations FDA inspectors cite.
Data Integrity Standards
The FDA expects every batch record entry to meet the ALCOA principles: attributable to a specific individual, legible and permanent, contemporaneous with the action, original, and accurate. Expanded versions of the framework add that data must also be complete, consistent in chronological sequence, enduring on media that survive the retention period, and available for inspection at any time.
Contemporaneous causes the most trouble in practice. Operators sometimes batch their entries at the end of a shift instead of recording each step as it happens. That produces exactly the gap investigators look for, because retroactive entries are less reliable and raise questions about whether the documented sequence matches what actually occurred on the floor. Automated data capture generates timestamped records without relying on human discipline, though it brings its own validation requirements.
Retention Periods and Electronic Records
Pharmaceutical production and control records must be retained for at least one year after the expiration date of the batch they document.10eCFR. 21 CFR 211.180 – General Requirements For certain over-the-counter products exempt from expiration dating, the period is three years after distribution. These timelines keep records available for audits, recalls, and adverse event investigations long after product has reached consumers.
Manufacturers that maintain batch records electronically must comply with 21 CFR Part 11, which sets the conditions under which the FDA treats electronic records and signatures as equivalent to paper. The regulation requires controls ensuring authenticity, integrity, and confidentiality from creation through receipt.11eCFR. 21 CFR Part 11 – Electronic Records; Electronic Signatures Each electronic signature must be unique to one individual and cannot be reused or reassigned. Systems must include audit trails that detect and log attempts to alter, delete, or backdate records. A poorly validated electronic system can create more compliance risk than the paper records it replaced, because the validation documentation itself becomes part of the quality record subject to inspection.
What Happens When Records Fall Short
Enforcement escalates in a predictable pattern.
Form 483 Observations
When FDA investigators inspect a facility and identify practices they believe violate the regulations, they document those findings on a Form 483, formally titled “Inspectional Observations.” A Form 483 is not a final determination that a violation occurred. It gives the company a chance to respond and implement corrective actions, ideally within 15 business days. The FDA can pursue further regulatory action at any time, regardless of whether corrective measures are underway.12Food and Drug Administration. Responding to FDA Form 483 Observations at the Conclusion of an Inspection
Warning Letters and Consent Decrees
If a company’s response is inadequate, or if the violations are serious enough, the FDA issues a Warning Letter demanding prompt corrective action. Unresolved Warning Letters can lead to consent decrees, court orders that bar the manufacturer from producing or distributing product until it demonstrates sustained compliance. Those situations regularly shut down production lines for months or years.
Seizures, Injunctions, and Criminal Penalties
The Federal Food, Drug, and Cosmetic Act gives the FDA authority to seek court-ordered seizure of adulterated or misbranded products and injunctions to halt ongoing violations.13Office of the Law Revision Counsel. 21 USC 332 – Injunction Proceedings Criminal penalties for a first violation reach up to one year of imprisonment, a fine of up to $1,000, or both. Where the person has a prior conviction or acted with intent to defraud or mislead, the ceiling rises to three years of imprisonment and fines up to $10,000.14Office of the Law Revision Counsel. 21 USC 333 – Penalties Those statutory fines look modest, but they apply per violation, and a single inspection can uncover dozens of separate violations across multiple batches.